Majority of New Cancer Therapies Not Producing Meaningful Clinical Benefit According to One Meta Analysis

Boston-area researchers representing elite centers from Beth Israel Deaconess Medical Center and Harvard Medical School to Brigham and Women’s Hospital and others recently analyzed 362 industry-sponsored Phase 3 randomized controlled trials centering on cancer from 2008 to 2017. With the results of the investigators study published in the Journal of the National Comprehensive Cancer Network, the team found that more than 80% of oncology-focused therapies investigated in Phase 3 trials failed to meet meaningful benefits such as the extension of survival.   87% of the studies analyzed turned out to be either false=-positive or true negative associated with overall survival goals.  Complicating the true picture as to whether material promise in oncology is commonplace, 58.4% of the analyzed trials eventually were deemed false-positive in relation to overall survival or “OS.”  Moreover, most of the underlying studies with negative findings turned out to represent “true-negative” findings, including a mere 0.9% false-negative findings.

TrialSite provides a breakdown of the meta-analysis results led by prominent researchers at Harvard Medical School and other preeminent institut...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee